VIATRIS INC. (VTRS) Current Ratio
- Current ratio · latest quarter: Value 1.58×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 1.58× | Current assets / current liabilities. $10.06B ÷ $6.35B ≈ 1.58× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 10.06B USD | Assets, Current |
| Current obligations | 6.35B USD | Liabilities, Current |
| Cash and equivalents | 886.50M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | Debt Securities, Available-for-sale, Current · Available-for-sale Securities, Current |
| Customer receivables | 3.13B USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory | 3.93B USD | Inventory, Net |
| Payables | (m) | |
| Borrowing debt due within one year | 1.74B USD | Long-term Debt, Current Maturities |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $10.06B | $6.35B | $886.50M | (m) | $3.13B | $3.93B | (m) | $1.74B | 1.58× |
| 2026-03-31 | $10.92B | $6.81B | $1.80B | (m) | $3.08B | $3.93B | (m) | $1.93B | 1.60× |
| 2025-12-31 | $9.79B | $7.09B | $1.32B | (m) | $3.03B | $4.00B | (m) | $1.93B | 1.38× |
| 2025-09-30 | $9.95B | $7.36B | $975.30M | (m) | $3.37B | $4.11B | (m) | $1.95B | 1.35× |
| 2025-06-30 | $9.77B | $7.13B | $566.40M | (m) | $3.26B | $4.26B | (m) | $1.68B | 1.37× |
| 2025-03-31 | $9.62B | $5.72B | $755.00M | (m) | $3.13B | $4.10B | (m) | $8.50M | 1.68× |
| 2024-12-31 | $9.52B | $5.78B | $734.80M | $38.00M | $3.22B | $3.85B | (m) | $8.30M | 1.65× |
| 2024-09-30 | $11.31B | $7.51B | $1.88B | (m) | $3.72B | $4.08B | (m) | $1.45B | 1.51× |
| 2024-06-30 | $11.79B | $7.71B | $917.20M | (m) | $3.57B | $3.94B | (m) | $2.37B | 1.53× |
| 2024-03-31 | $12.92B | $7.76B | $1.01B | (m) | $3.63B | $3.82B | (m) | $1.90B | 1.67× |
| 2023-12-31 | $12.98B | $7.78B | $991.90M | $37.00M | $3.70B | $3.47B | (m) | $1.94B | 1.67× |
| 2023-09-30 | $10.93B | $6.83B | $1.31B | (m) | $3.74B | $3.67B | (m) | $1.31B | 1.60× |
| 2023-06-30 | $9.78B | $6.52B | $629.20M | (m) | $3.61B | $3.64B | (m) | $1.33B | 1.50× |
| 2023-03-31 | $9.63B | $6.11B | $506.60M | (m) | $3.50B | $3.66B | (m) | $508.70M | 1.58× |
| 2022-12-31 | $10.64B | $6.75B | $1.26B | $35.30M | $3.81B | $3.52B | (m) | $1.26B | 1.58× |
| 2022-09-30 | $10.49B | $6.52B | $646.70M | (m) | $3.33B | $3.38B | (m) | $763.80M | 1.61× |
| 2022-06-30 | $11.18B | $7.68B | $664.70M | (m) | $3.74B | $3.61B | (m) | $768.20M | 1.46× |
| 2022-03-31 | $11.74B | $9.64B | $752.40M | (m) | $4.09B | $3.80B | (m) | $2.61B | 1.22× |
| 2021-12-31 | $10.90B | $9.88B | $701.20M | $38.20M | $4.27B | $3.98B | (m) | $1.88B | 1.10× |
| 2021-09-30 | $11.31B | $10.10B | $756.60M | (m) | $4.35B | $4.08B | (m) | $1.91B | 1.12× |
| 2021-06-30 | $11.75B | $10.13B | $673.90M | (m) | $4.48B | $4.49B | (m) | $2.18B | 1.16× |
| 2021-03-31 | $12.32B | $9.98B | $806.90M | (m) | $4.53B | $4.94B | (m) | $2.30B | 1.23× |
| 2020-12-31 | $12.87B | $10.56B | $844.40M | $39.10M | $4.84B | $5.47B | (m) | $2.31B | 1.22× |
| 2020-09-27 | $11.41B | $79.00M | (m) | (m) | (m) | (m) | (m) | (m) | 144.47× |
| 2020-06-28 | $11.41B | $27.80M | (m) | (m) | (m) | (m) | (m) | (m) | 410.50× |
| 2019-12-31 | $6.76B | $5.57B | $475.60M | $26.80M | $3.06B | $2.67B | (m) | $1.51B | 1.21× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |